Positron puts financial house in order
PET camera developer Positron is close to completing two dealsthat will put the Houston-based company back on firm financialfooting. The deals are intended to solve a cash crunch that hasdogged Positron since last November. In the first piece of the
PET camera developer Positron is close to completing two dealsthat will put the Houston-based company back on firm financialfooting. The deals are intended to solve a cash crunch that hasdogged Positron since last November.
In the first piece of the financial puzzle, Positron has secureda $1 million revolving line of credit with Boston Financial &Equity that allows the vendor to borrow up to 80% of its accountsreceivables. The financing will give Positron short-term creditflexibility and will enable the company to finance the constructionof PET scanners as it fulfills customer orders, according to CFODavid Rodrigue.
In addition, Positron plans to place up to 2.3 million sharesof preferred stock with private investors. The company hopes toraise between $2 million and $3.5 million with the offering.
Positron will use the funds for working capital and to bringthe company back into compliance with listing requirements forNASDAQ's national market system. Positron has fallen below NASDAQ's$4 million minimum net worth requirement and its stock will bemoved to NASDAQ's small cap market unless it raises more funds.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
